ReliTecan® (Irinotecan hydrochloride) is an antineoplastic agent of topoisomerase I inhibitor class. Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extract from plants such as Camptotheca acuminata or is chemically synthesized. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I DNA complex and prevent religation of these single-strand breaks.
The approved indications include first-line therapy for patients with metastatic carcinoma of the colon or rectum used in combination with 5-fluorouracil (5-FU) and leucovorin (LV)) and patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
is available in two formulations ie100mg / 5ml and 40mg/ 2ml